微創醫療(00853.HK)戰略投資蘇州阿格斯醫療技術
格隆匯10月29日丨微創醫療(00853.HK)公吿，於2021年10月29日， 公司附屬公司上海微創投資控股有限公司("微創投資")與蘇州阿格斯醫療技術有限公司("阿格斯")及其現有股東簽署股權轉讓及增資協議，據此微創投資同意以人民幣3.723億元的總代價自阿格斯部分現有股東("賣方")收購其所有持有的阿格斯38.33%的權益及向阿格斯新增註冊資本("轉讓與增資")。於轉讓與增資完成後，集團將持有阿格斯51%的權益，而阿格斯將入賬列為集團的附屬公司。
另外，倘阿格斯完成相應研發進程和生產提升的里程碑，阿格斯部分現有股東，最早於2022年12月31日及不遲於2024年6月30日，有權要求集團以約人民幣2.68億元的代價進一步收購其直接或間接持有的阿格斯的權益(合共約為轉讓與增資完成後31.55%的權益)。
阿格斯成立於2016年，其主營業務包括設計、開發以及銷售用於血管內光學干涉斷層成像(OpticalCoherenceTomography,OCT)系統的解決方案，目前已成功自主研發了ArgusClarityOCT系統及ArgusNOPURGETM全封閉式免沖洗一次性成像導管。其中，ArgusNOPURGETM已通過國家創新醫療器械特別審批程序("綠色通道")，並於2021年3月取得國家藥監局("NMPA")頒發的註冊證。其目前正在進行歐盟CE認證申請。ArgusNOPURGETM可降低由於造影劑沖洗造成導管內雜質進入血液的潛在風險，同時能夠減少造影劑的使用量，降低患者的腎功能負擔，該技術亦可減少手術步驟和時間。
本次戰略合作將會進一步完善集團在泛血管領域的一體化精準診療解決方案，是集團在冠心病治療全解醫療方案領域的重要佈局，同時也將促進阿格斯的OCT系統及其免沖洗一次性成像導管的市場拓展，從而為心血管醫生提供更精準的醫療手段，讓更多冠心病患者受益於前沿醫療科技。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
